Ratings The Beauty Health Company

Equities

SKIN

US88331L1089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.24 ^USD	+5.88%		-0.92%	+4.18%

Apr. 10	Beauty Health Names Sheri Lewis as Chief Supply Chain, Operations Officer	MT
Apr. 09	The Beauty Health Company Announces Termination of Brad Hauser as Chief Operating Officer	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Personal Products

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
THE BEAUTY HEALTH COMPANY	+4.18%	400M		D+
L'ORÉAL	-3.33%	249B		B-
KAO CORPORATION	+10.09%	18.86B		B+
GALDERMA GROUP AG	0.00%	17.37B	-	-
SHISEIDO COMPANY, LIMITED	-1.32%	10.65B		A-
COTY INC.	-7.73%	10.26B		A-
AMOREPACIFIC CORPORATION	+3.86%	6.72B		B+
PROYA COSMETICS CO.,LTD.	+9.76%	5.94B		B
NATURA &CO HOLDING S.A.	-0.06%	4.55B		B+
INTER PARFUMS, INC.	-16.98%	3.83B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes